Fig. 1From: Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategiesTumor cells inhibit T cell activation by expressing PD-L1 on their cell surface, and PD-1/PD-L1 inhibitors reactivate T cells by specifically binding to PD-1/PD-L1Back to article page